223 related articles for article (PubMed ID: 10518631)
1. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery.
Benet LZ; Izumi T; Zhang Y; Silverman JA; Wacher VJ
J Control Release; 1999 Nov; 62(1-2):25-31. PubMed ID: 10518631
[TBL] [Abstract][Full Text] [Related]
2. Active secretion and enterocytic drug metabolism barriers to drug absorption.
Wacher VJ; Salphati L; Benet LZ
Adv Drug Deliv Rev; 2001 Mar; 46(1-3):89-102. PubMed ID: 11259835
[TBL] [Abstract][Full Text] [Related]
3. Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs.
Patel J; Mitra AK
Pharmacogenomics; 2001 Nov; 2(4):401-15. PubMed ID: 11722289
[TBL] [Abstract][Full Text] [Related]
4. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein.
Zhang Y; Benet LZ
Clin Pharmacokinet; 2001; 40(3):159-68. PubMed ID: 11327196
[TBL] [Abstract][Full Text] [Related]
5. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4.
Cummins CL; Jacobsen W; Benet LZ
J Pharmacol Exp Ther; 2002 Mar; 300(3):1036-45. PubMed ID: 11861813
[TBL] [Abstract][Full Text] [Related]
6. In silico modeling for the nonlinear absorption kinetics of UK-343,664: a P-gp and CYP3A4 substrate.
Abuasal BS; Bolger MB; Walker DK; Kaddoumi A
Mol Pharm; 2012 Mar; 9(3):492-504. PubMed ID: 22264132
[TBL] [Abstract][Full Text] [Related]
7. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
[TBL] [Abstract][Full Text] [Related]
8. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.
Darwich AS; Neuhoff S; Jamei M; Rostami-Hodjegan A
Curr Drug Metab; 2010 Nov; 11(9):716-29. PubMed ID: 21189140
[TBL] [Abstract][Full Text] [Related]
9. New insights into drug absorption: studies with sirolimus.
Paine MF; Leung LY; Watkins PB
Ther Drug Monit; 2004 Oct; 26(5):463-7. PubMed ID: 15385826
[TBL] [Abstract][Full Text] [Related]
10. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
[TBL] [Abstract][Full Text] [Related]
11. Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass.
Bruyère A; Declèves X; Bouzom F; Ball K; Marques C; Treton X; Pocard M; Valleur P; Bouhnik Y; Panis Y; Scherrmann JM; Mouly S
Mol Pharm; 2010 Oct; 7(5):1596-607. PubMed ID: 20604570
[TBL] [Abstract][Full Text] [Related]
12. Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data.
Benet LZ; Cummins CL; Wu CY
Curr Drug Metab; 2003 Oct; 4(5):393-8. PubMed ID: 14529371
[TBL] [Abstract][Full Text] [Related]
13. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics.
Wacher VJ; Silverman JA; Zhang Y; Benet LZ
J Pharm Sci; 1998 Nov; 87(11):1322-30. PubMed ID: 9811484
[TBL] [Abstract][Full Text] [Related]
14. A Mathematical simulation to explain the coordinated functions of efflux and metabolism limiting the transport of anti-HIV agents across Caco-2 cells.
Patel J; Hussain A; Pal D; Mitra AK
Am J Ther; 2004; 11(2):114-23. PubMed ID: 14999363
[TBL] [Abstract][Full Text] [Related]
15. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes.
Benet LZ; Cummins CL; Wu CY
Int J Pharm; 2004 Jun; 277(1-2):3-9. PubMed ID: 15158963
[TBL] [Abstract][Full Text] [Related]
16. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir.
Huisman MT; Smit JW; Wiltshire HR; Hoetelmans RM; Beijnen JH; Schinkel AH
Mol Pharmacol; 2001 Apr; 59(4):806-13. PubMed ID: 11259625
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the Role of P-glycoprotein (P-gp)-Mediated Efflux in the Intestinal Absorption of Common Substrates with Elacridar, a P-gp Inhibitor, in Rats.
Suzuki K; Taniyama K; Aoyama T; Watanabe Y
Eur J Drug Metab Pharmacokinet; 2020 Jun; 45(3):385-392. PubMed ID: 32078103
[TBL] [Abstract][Full Text] [Related]
18. A novel nanocapsule delivery system to overcome intestinal degradation and drug transport limited absorption of P-glycoprotein substrate drugs.
Nassar T; Rom A; Nyska A; Benita S
Pharm Res; 2008 Sep; 25(9):2019-29. PubMed ID: 18581211
[TBL] [Abstract][Full Text] [Related]
19. Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption--theoretical approach.
Ito K; Kusuhara H; Sugiyama Y
Pharm Res; 1999 Feb; 16(2):225-31. PubMed ID: 10100307
[TBL] [Abstract][Full Text] [Related]
20. Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine.
Suzuki H; Sugiyama Y
Eur J Pharm Sci; 2000 Nov; 12(1):3-12. PubMed ID: 11121729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]